Dongwha Pharm.Co.Ltd Inkomsten in het verleden
Verleden criteriumcontroles 2/6
Dongwha Pharm.Co.Ltd has been growing earnings at an average annual rate of 11.8%, while the Pharmaceuticals industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 6.3% per year. Dongwha Pharm.Co.Ltd's return on equity is 3.4%, and it has net margins of 3.4%.
Belangrijke informatie
11.8%
Groei van de winst
11.8%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 11.3% |
| Inkomstengroei | 6.3% |
| Rendement op eigen vermogen | 3.4% |
| Nettomarge | 3.4% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Dongwha Pharm.Co.Ltd's (KRX:000020) Promising Earnings May Rest On Soft Foundations
Mar 26
We're Not Counting On Dongwha Pharm.Co.Ltd (KRX:000020) To Sustain Its Statutory Profitability
Dec 19Recent updates
Dongwha Pharm.Co.Ltd's (KRX:000020) Promising Earnings May Rest On Soft Foundations
Mar 26Is Dongwha Pharm.Co.,Ltd (KRX:000020) A Smart Pick For Income Investors?
Apr 28These 4 Measures Indicate That Dongwha Pharm.Co.Ltd (KRX:000020) Is Using Debt Safely
Mar 11Dongwha Pharm.Co.,Ltd (KRX:000020) Has A ROE Of 8.6%
Feb 22Is Dongwha Pharm.Co.Ltd's (KRX:000020) Share Price Gain Of 102% Well Earned?
Feb 07Should Dongwha Pharm.Co.,Ltd (KRX:000020) Be Part Of Your Dividend Portfolio?
Jan 23Is Dongwha Pharm.Co.,Ltd (KRX:000020) Popular Amongst Insiders?
Jan 08
Dongwha Pharm.Co.,Ltd (KRX:000020) Pays A ₩120 Dividend In Just Four Days
Dec 24We're Not Counting On Dongwha Pharm.Co.Ltd (KRX:000020) To Sustain Its Statutory Profitability
Dec 19Is Dongwha Pharm.Co.Ltd (KRX:000020) Using Too Much Debt?
Dec 04Can Dongwha Pharm.Co.,Ltd (KRX:000020) Improve Its Returns?
Nov 19Opbrengsten en kosten
Hoe Dongwha Pharm.Co.Ltd geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 405,746 | 13,902 | 159,010 | 21,555 |
| 31 Mar 24 | 380,574 | 17,888 | 151,392 | 21,131 |
| 31 Dec 23 | 361,109 | 27,438 | 143,565 | 21,548 |
| 30 Sep 23 | 361,326 | 29,155 | 133,492 | 26,919 |
| 30 Jun 23 | 357,324 | 29,177 | 127,099 | 27,378 |
| 31 Mar 23 | 354,552 | 27,685 | 129,165 | 20,524 |
| 31 Dec 22 | 340,426 | 20,383 | 125,774 | 19,285 |
| 30 Sep 22 | 332,285 | 22,907 | 126,486 | 8,965 |
| 30 Jun 22 | 317,901 | 17,410 | 118,876 | 11,463 |
| 31 Mar 22 | 306,485 | 17,660 | 108,251 | 17,336 |
| 31 Dec 21 | 293,018 | 17,870 | 103,215 | 17,338 |
| 30 Sep 21 | 285,371 | 19,928 | 98,998 | 17,459 |
| 30 Jun 21 | 282,868 | 31,238 | 95,832 | 17,377 |
| 31 Mar 21 | 276,899 | 31,693 | 93,364 | 17,383 |
| 31 Dec 20 | 272,075 | 28,508 | 92,558 | 16,912 |
| 30 Sep 20 | 286,746 | 28,405 | 89,901 | 17,156 |
| 30 Jun 20 | 294,395 | 16,884 | 90,649 | 16,987 |
| 31 Mar 20 | 299,490 | 9,533 | 91,424 | 16,581 |
| 31 Dec 19 | 307,150 | 9,116 | 90,636 | 16,332 |
| 30 Sep 19 | 299,195 | 4,881 | 91,613 | 16,408 |
| 30 Jun 19 | 299,893 | 5,823 | 90,683 | 16,183 |
| 31 Mar 19 | 304,302 | 7,202 | 89,285 | 15,781 |
| 31 Dec 18 | 306,603 | 10,069 | 85,519 | 15,605 |
| 31 Dec 17 | 258,882 | 47,009 | 79,450 | 14,078 |
Kwaliteitswinsten: A000020 has high quality earnings.
Groeiende winstmarge: A000020's current net profit margins (3.4%) are lower than last year (8.2%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: A000020's earnings have grown by 11.8% per year over the past 5 years.
Versnelling van de groei: A000020's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: A000020 had negative earnings growth (-52.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (21.9%).
Rendement op eigen vermogen
Hoge ROE: A000020's Return on Equity (3.4%) is considered low.